Open access

Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Older Adults in California and Louisiana, August-December 2025

L. Zambrano T. Yu J. Mateus X. Zhao K. Andersen S. Valluri B. Karakuzu Ikizler R. Nepal A. J. MacNeil H. Volkman

Jul 2026 · medRxiv · 0 citations

Medicine

TL;DR

VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66) and VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).

Abstract

Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults [≥]65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).

DOI Semantic Scholar

Read PDF

Similar papers

Review Aug 2026

Updated Evidence for COVID-19, RSV, and Influenza Vaccines for 2025-2026

( N Engl J Med . 2025 Dec 4;393(22):2221–2242. doi: 10.1056/NEJMsa2514268) In the United States, changes in federal messaging surrounding vaccines have caused disruption to guidance for immunization, though it is known that respiratory illnesses such as respiratory syncytial virus (RSV), influenza, and severe ac...

J. Scott, Michael S Abers, HK Marwah et al. · Obstetric Anesthesia Digest · 0 citations

Open access Aug 2026

2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults.

BNT162b2 provided protection against COVID-19-associated outcomes of ED, UC or hospitalization among non-immunocompromised U.S. adults, including those with UMCs, over the course of the 2024-2025 respiratory virus season, supporting continued vaccine recommendations.

Tara Ahi, K. Andersen, J. Mateus et al. · Vaccine · 0 citations

Open access Aug 2026

Effectiveness of coronavirus disease 2019 (COVID-19) original vaccines to prevent COVID-19-related hospitalisations among Alaska Native peoples, January 2021–October 2022

Waning effectiveness with time and the introduction of new variants supports the need to stay up-to-date with SARS-CoV-2 vaccination.

Ian Blake, R. Singleton, Dana J. T. Bruden et al. · International Journal of Cir... · 0 citations

Aug 2026

COVIDTests.gov Test Kits Associated With Expanded SARS-CoV-2 Testing Among Recipients.

J. Sanborn, M. Robertson, D. Nash et al. · American Journal of Public H... · 0 citations

Open access Aug 2026

Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands.

It was found that, during a 5-month study period with low incidence, JN.1-vaccination provided limited added protection in preventing SARS-CoV-2 infection.

Anne J. Huiberts, D. Eggink, B. de Gier et al. · Vaccine · 0 citations

Open access Sep 2026

Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 Season

Key Points Question What is the estimated effectiveness of the respiratory syncytial virus (RSV) vaccines against RSV-related hospitalization and death among US adults 65 years or older? Findings In this cohort study of 14 819 226 Medicare fee-for-service beneficiaries, both the RSVPreF3+AS01 and RSVpreF RSV vaccines p...

Yun Lu, Elizabeth R. Smith, R. McEvoy et al. · JAMA Network Open · 0 citations